Applied dna advances commercialization of linea(tm) ivt platform, appoints beverly wolgast as executive director of quality and cgmp programs

Experienced biopharma/pharmaceutical executive to lead implementation of cgmp-quality lineadna™ capability for ivt mrna production previously led manufacturing operations scale-up for the biontech/pfizer mrna covid-19 vaccine at cdmo division of maravai lifesciences stony brook, ny / accesswire / september 6, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced the appointment of beverly wolgast, ph.d., as executive director of quality and cgmp programs.
APDN Ratings Summary
APDN Quant Ranking